Clinical Trial Update: LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating LY3200882 in combination with capecitabine for advanced, TGF-beta-activated colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• LY3200882

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Colorectal Cancer Metastatic | Phase 1, Phase 2 | Status: WITHDRAWN